| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| 99213 |
Office or other outpatient visit for the evaluation and management of an established patient, low complexity |
19,958 |
15,599 |
$1.30M |
| 99214 |
Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity |
9,297 |
6,674 |
$471K |
| 99283 |
Emergency department visit for the evaluation and management, moderate severity |
2,894 |
2,566 |
$368K |
| 99285 |
Emergency department visit for the evaluation and management, high severity with immediate threat to life |
550 |
434 |
$187K |
| 36415 |
Collection of venous blood by venipuncture |
16,762 |
13,955 |
$113K |
| 80053 |
Comprehensive metabolic panel |
2,882 |
2,570 |
$97K |
| 0241U |
Neonatal screening for hereditary disorders, genomic sequence analysis panel |
477 |
444 |
$84K |
| 99284 |
Emergency department visit for the evaluation and management, high severity |
1,297 |
1,095 |
$81K |
| 98941 |
Chiropractic manipulative treatment; spinal, 3-4 regions |
2,304 |
1,394 |
$68K |
| 85025 |
Blood count; complete (CBC), automated, and automated differential WBC count |
3,510 |
3,057 |
$68K |
| 90834 |
Psychotherapy, 45 minutes with patient |
1,343 |
735 |
$55K |
| 99282 |
Emergency department visit for the evaluation and management, low to moderate severity |
483 |
436 |
$49K |
| 87426 |
Infectious agent antigen detection, SARS-CoV-2 (COVID-19) |
716 |
686 |
$47K |
| 99211 |
Office or other outpatient visit for the evaluation and management of an established patient, minimal severity |
540 |
435 |
$40K |
| 80061 |
Lipid panel |
1,137 |
1,067 |
$38K |
| J3490 |
Unclassified drugs |
736 |
299 |
$20K |
| 98940 |
|
866 |
486 |
$17K |
| 82306 |
Vitamin D; 25 hydroxy, includes fraction(s), if performed |
247 |
205 |
$16K |
| 99203 |
Office or other outpatient visit for the evaluation and management of a new patient, low complexity |
167 |
150 |
$14K |
| 99212 |
Office or other outpatient visit for the evaluation and management of an established patient, straightforward |
245 |
224 |
$12K |
| U0003 |
Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r |
100 |
98 |
$10K |
| 0001A |
|
342 |
328 |
$9K |
| 83036 |
Hemoglobin; glycosylated (A1C) |
438 |
412 |
$9K |
| 0002A |
|
308 |
300 |
$8K |
| 90471 |
Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine |
607 |
558 |
$8K |
| 81001 |
|
467 |
421 |
$7K |
| 87651 |
Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe |
146 |
139 |
$6K |
| 96374 |
Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance |
117 |
102 |
$5K |
| 86140 |
|
275 |
224 |
$5K |
| 80048 |
Basic metabolic panel (calcium, ionized) |
199 |
170 |
$5K |
| 99391 |
Periodic comprehensive preventive medicine reevaluation, established patient, infant (under 1 year) |
48 |
40 |
$5K |
| 84443 |
Thyroid stimulating hormone (TSH) |
194 |
159 |
$4K |
| 59025 |
Fetal non-stress test |
20 |
13 |
$4K |
| 87510 |
|
204 |
190 |
$4K |
| 87660 |
|
204 |
190 |
$3K |
| 87480 |
|
204 |
190 |
$3K |
| 11721 |
|
191 |
85 |
$3K |
| 90686 |
|
454 |
437 |
$3K |
| 96372 |
Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular |
103 |
89 |
$3K |
| 99392 |
Periodic comprehensive preventive medicine reevaluation, established patient, early childhood (1-4 years) |
28 |
27 |
$2K |
| 82728 |
|
109 |
87 |
$2K |
| 87502 |
Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets |
41 |
36 |
$2K |
| 82607 |
|
107 |
91 |
$2K |
| 83735 |
|
160 |
130 |
$2K |
| 85027 |
|
81 |
76 |
$2K |
| 82043 |
|
59 |
53 |
$2K |
| 96375 |
Therapeutic injection; each additional sequential IV push |
31 |
25 |
$2K |
| 82570 |
|
78 |
68 |
$2K |
| 93005 |
Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report |
50 |
41 |
$1K |
| 87491 |
Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe |
13 |
13 |
$1K |
| Q3014 |
Telehealth originating site facility fee |
52 |
50 |
$1K |
| 0004A |
|
45 |
45 |
$1K |
| 80307 |
Drug test(s), presumptive, any number of drug classes; immunoassay |
51 |
38 |
$1K |
| 84484 |
|
47 |
39 |
$906.41 |
| U0005 |
Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 |
56 |
55 |
$876.35 |
| 0124A |
|
40 |
39 |
$814.31 |
| 71045 |
Radiologic examination, chest; single view |
13 |
13 |
$787.15 |
| J1040 |
Injection, methylprednisolone acetate, 80 mg |
37 |
29 |
$728.32 |
| 83605 |
|
29 |
26 |
$698.39 |
| 80069 |
|
17 |
13 |
$618.13 |
| 87591 |
Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe |
13 |
13 |
$594.33 |
| 85610 |
|
39 |
24 |
$531.74 |
| 0352U |
|
46 |
44 |
$490.60 |
| 80306 |
|
38 |
26 |
$481.88 |
| 87635 |
Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe |
63 |
61 |
$433.28 |
| J1885 |
Injection, ketorolac tromethamine, per 15 mg |
29 |
25 |
$311.69 |
| 85652 |
|
30 |
24 |
$297.88 |
| J3010 |
Injection, fentanyl citrate, 0.1 mg |
57 |
48 |
$268.23 |
| G0008 |
Administration of influenza virus vaccine |
21 |
20 |
$182.77 |
| 84156 |
|
17 |
12 |
$146.14 |
| 90472 |
Immunization administration, each additional vaccine (list separately) |
29 |
29 |
$77.88 |
| 99188 |
|
12 |
12 |
$74.68 |
| J2250 |
Injection, midazolam hydrochloride, per 1 mg |
12 |
12 |
$33.44 |
| J1100 |
Injection, dexamethasone sodium phosphate, 1 mg |
15 |
15 |
$20.57 |
| 91300 |
|
47 |
34 |
$20.09 |